Profoundbio Announces Completion Of $70 Million Series A+ Financing To Advance Antibody-Drug Conjugate (Adc) Programs Into The Clinic

Jun 02, 2022•about 3 years ago

Amount Raised

$70 Million

Round Type

series a

Woodinville

Description

ProfoundBio, a biotech company focusing on the development of novel targeted therapies, announced the closing of a $70 million Series A+ financing round led by Sequoia China. Current investors Lilly Asia Venture, Oriza, Chang'an Capital, LYFE Capital, and K2VC also participated in this round of financing. ProfoundBio has raised a total of more than $138 million in the past two years. Following the closing, Lynn Yang from Sequoia China will be joining the company's Board of Directors.

Company Information

Company

Profound Bio

Location

Woodinville, Washington, United States

About

ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer. Built on innovative technology platforms, ProfoundBio has developed a pipeline consisting of multiple solid tumor-targeting drug candidates that are currently in discovery and preclinical development stages. ProfoundBio has operations in both the greater Seattle area, WA, USA and Suzhou, China. For more information, please visit www.profoundbio.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech